Source:http://linkedlifedata.com/resource/pubmed/id/11744828
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2001-12-17
|
| pubmed:abstractText |
No effective salvage regimen has been defined for patients with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) who do not respond to first-line chemotherapy that contains anthracycline. Combined dexamethasone, cytosine arabinoside, and cisplatin (DHAP) and etoposide, methylprednisolone, cytosine arabinoside, and cisplatin (ESHAP) have shown good response rates in HIV-negative patients with relapsed lymphomas. We retrospectively analyzed patients with refractory or relapsed AIDS-NHL who had been treated with either DHAP or ESHAP to evaluate the feasibility and efficacy of these regimens. Twenty-six patients with refractory or relapsed AIDS-NHL were treated between 1990 and 1999 either with DHAP ( n = 13) or with ESHAP ( n = 13). Only 1 patient from each group (8%) had achieved complete remission with any previous therapy, and most had progressive disease after the regimen immediately preceding DHAP or ESHAP. In the ESHAP group, 4 patients (31%) achieved complete remission (CR) and 3 patients (23%) attained partial remission (PR) for an overall response rate of 54%. The median survival was 7.1 months (range, 1-58.9+ months) from the time ESHAP was begun. Among the 3 patients with primary refractory lymphoma, there was 1 CR, 1 PR, and one patient with stable disease. In contrast, only 1 PR (7%) was observed with DHAP; the median survival was 3 months. Myelosuppression was the most significant toxicity with grade 4 neutropenia occurring in all who received ESHAP and in 54% of patients treated with DHAP. Neutropenic fever occurred in 8 (62%) ESHAP-treated and 6 (46%) DHAP-treated patients. Although hematologic toxicity is profound, ESHAP appears to be an active salvage regimen for patients with relapsed or refractory AIDS-NHL.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Methylprednisolone
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1525-4135
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
416-21
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11744828-Adult,
pubmed-meshheading:11744828-Aged,
pubmed-meshheading:11744828-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11744828-Antiviral Agents,
pubmed-meshheading:11744828-Cisplatin,
pubmed-meshheading:11744828-Cytarabine,
pubmed-meshheading:11744828-Dexamethasone,
pubmed-meshheading:11744828-Drug Therapy, Combination,
pubmed-meshheading:11744828-Etoposide,
pubmed-meshheading:11744828-Humans,
pubmed-meshheading:11744828-Lymphoma, AIDS-Related,
pubmed-meshheading:11744828-Lymphoma, Non-Hodgkin,
pubmed-meshheading:11744828-Male,
pubmed-meshheading:11744828-Methylprednisolone,
pubmed-meshheading:11744828-Middle Aged,
pubmed-meshheading:11744828-Recurrence,
pubmed-meshheading:11744828-Remission Induction,
pubmed-meshheading:11744828-Retrospective Studies,
pubmed-meshheading:11744828-Salvage Therapy,
pubmed-meshheading:11744828-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|